Product news

Share this article:
Amgen said the European Commission has granted a conditional marketing authorization for Vectibix (panitumumab) as monotherapy for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions